5 / 17
Page 34
Notes:
conferenceseries
.com
Euro Pathology 2018 | Hematologic Oncology 2018
June 20-21, 2018
Volume 8
Journal of Clinical & Experimental Pathology
ISSN : 2161-0681
15
th
EUROPEAN PATHOLOGY CONGRESS
&
LEUKEMIA AND HEMATOLOGIC ONCOLOGY
June 20-21, 2018 | Paris, France
14
th
International Conference on
JOINT EVENT
Immunohistochemical surrogate for molecular subtype of breast carcinoma and its correlation with cyclin D1
expression: An Indian scenario
Gireesha Rawal, Chintamani, A K Mandal and Indrani Dhawan
Vardhman Mahavir Medical College and Safdarjung Hospital, India
V
arious prognostic parameters have been described and validated for breast cancer, but the search for newer prognostic factors
continues since existing parameters do not provide sufficient information for accurate risk assessment and tailor-made treatment
planning. Thus, in the St. Gallen International Expert Consensus on primary therapy of early breast cancer, 2011, breast carcinoma
was classified on molecular basis. Further this correlated well with immunohistochemical expression of the tumours and was called
surrogate molecular classification. Studies on Cyclin D1 have shown inconsistent and conflicting results with regards to its role in
prognosis. This study was aimed at classifying breast carcinoma using surrogate molecular classification into immunophenotypes,
studying the immunohistochemical expression of Cyclin D1, and correlating Cyclin D1 as well as immunophenotypes with various
parameters. Fifty cases of breast carcinoma were studied and their pTNM staging and Bloom Richardson (BR) grading done.
Immunohistochemistry for Cyclin D1, ER, PR, Her2neu and Ki-67 was performed, and they were classified into immunophenotypes.
Majority of the cases (40%) were Luminal A subtype, and least (16%) were triple negative. Cyclin D1 positivity was seen in
54% cases. Cyclin D1 showed statistically significant decreasing positivity with increasing grade as well as with increasing stage.
On correlating immunophenotype with Cyclin D1, 75% Luminal A, 75% Luminal B, 20% Her2neu enriched, and 12.5% triple
negative cases were positive for Cyclin D1. This decreasing trend was statistically significant. This is one of the initial studies from
India analyzing immunophenotypes and correlating them with Cyclin D1 expression, in addition to other parameters. The significant
association of Cyclin D1 with low stage, low grade and Luminal immunophenotypes may indicate that Cyclin D1 is a good predictive
and prognostic factor that closely interacts with hormone signaling pathway. This may aid in investigating the response and clinical
outcomes of treatment targeting Cyclin D1.
Biography
Gireesha Rawal has completed her Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from Vardhman Mahavir Medical College and Safdarjung
Hospital, New Delhi, and she is currently pursuing Post-graduation in Pathology from Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi.
Her areas of interest include breast pathology, immunopathology and female genital tract pathology. She has published many case reports and papers in reputed
journals.
gireesharawal@yahoo.inGireesha Rawal et al., J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C1-045